The GNRH1 Knockout TE1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human esophageal squamous cell carcinoma line TE1. This heterogeneous pool of cells harbors disruptions in the GNRH1 gene, which encodes the gonadotropin-releasing hormone (GnRH) decapeptide. The use of CRISPR/Cas9-mediated gene disruption generates a loss-of-function model suitable for studying the autocrine and paracrine roles of GNRH1 signaling in cancer biology without selecting for specific clonal editing events.
TE1 is a well-differentiated human esophageal squamous cell carcinoma cell line originally established from a Japanese patient. These cells display characteristic epithelial morphology and are extensively employed in research on esophageal carcinogenesis, tumor invasion, and drug responsiveness. The TE1 line provides a clinically relevant in vitro system for investigating molecular mechanisms underlying esophageal cancer progression and for evaluating potential therapeutic interventions.
GNRH1 is best known as the hypothalamic neurohormone that stimulates pituitary gonadotropin secretion via its cognate G protein-coupled receptor GNRHR. At the molecular level, GNRH1 binding to GNRHR activates Gq/11 proteins, leading to phospholipase C-mediated generation of inositol trisphosphate (IP3) and diacylglycerol, calcium mobilization, and protein kinase C (PKC) activation. This triggers downstream mitogen-activated protein kinase (MAPK) cascades, including the phosphorylation of ERK1/2 and JNK, and the activation of transcription factors such as CREB, AP-1, and NFAT. In peripheral tissues, including esophageal cancer cells, GNRH1 signaling modulates cell proliferation and apoptosis through these pathways. The expression and activity of GNRH1 are regulated by upstream factors such as kisspeptin, neurokinin B, and gonadal steroids, and it interacts with GNRHR, G proteins, and ??-arrestins.
In the context of esophageal squamous cell carcinoma, aberrant GNRH1 autocrine/paracrine loops may contribute to tumor growth and survival. By disrupting GNRH1 in TE1 cells, this polyclonal knockout model permits the dissection of GNRH1-dependent signaling and its impact on cancer cell phenotypes. It is particularly valuable for investigating how loss of GNRH1 affects proliferation, migration, and apoptosis, and for assessing the functional consequences of GnRH analog treatment. This model also enables examination of crosstalk between the GnRH pathway and other signaling networks implicated in carcinogenesis.
Researchers can utilize these polyclonal GNRH1 knockout cells in a variety of assays, including cell proliferation analysis (e.g., MTT, CCK-8), Transwell migration and invasion studies, and Annexin V/PI apoptosis assays. Molecular endpoints can be evaluated by quantitative RT-PCR, Western blotting for phosphorylated ERK and AKT, and transcriptome profiling via RNA-seq. The cells are suitable for screening GnRH analogs for anticancer activity and for functional genomics investigations into the role of GNRH1 in esophageal cancer. For additional technical information and ordering details, please contact Ascent Research.
